摘要
肿瘤浸润性淋巴细胞(tumor-infiltrating lymphocytes,TILs)免疫治疗通过体外分离、扩增和回输患者自己的能特异性识别肿瘤组织的肿瘤浸润性T淋巴细胞来治疗肿瘤,是目前主要的过继性细胞免疫治疗类型之一。TILs已在用于实体瘤治疗的临床试验,尤其是在用于转移性黑色素瘤患者治疗时显现有令人鼓舞的临床效果。然而,TILs治疗也面临一些挑战,如肿瘤相关抗原反应性T细胞难以分离及其在体内的持久性和安全性等。本文概要介绍TILs治疗的产品生产过程、临床应用的可行性、临床研究进展,以及TILs治疗面临的挑战和解决措施,供TILs治疗的研究与开发者参考。
Tumor-infiltrating lymphocytes(TILs)therapy is one of the main types of adoptive cellular immunotherapy by harvesting infiltrated lymphocytes from tumors followed by ex vivo expansion and then infusing them back to patients themselves.TILs therapy has shown encouraging clinical effects in clinical trials against solid tumors,especially in treating metastatic melanoma.Nevertheless,various barriers restrict the efficacy and prevent the widespread use of TILs therapy,such as the difficulty of isolating tumor-associated antigen-reactive T cells and their persistence and clinical safety in vivo.Herein,we summarize the manufacturing process of TILs and the feasibility analysis of the clinical application and discuss the advances in clinical trials and the current obstacles with some strategies to be overcome,shedding light of the development of the next generation of TILs therapy.
作者
杨涵
陈超
王冲
YANG Han;CHEN Chao;WANG Chong(Shanghai Center for Drug Evaluation and Inspection,Shanghai 201210,China)
出处
《上海医药》
CAS
2022年第11期17-21,共5页
Shanghai Medical & Pharmaceutical Journal
关键词
肿瘤浸润性淋巴细胞
实体瘤
临床研究
tumor-infiltrating lymphocytes
solid tumors
clinical trials
